Evaluation and Comparison of the Seroprevalence of Hepatitis B and Hepatitis C Virus Infection in Patients Admitted to Clinics at the “Mogadishu, Turkey Recep Tayyip Erdogan Training and Research Hospital” in Somalia

Öz

Objective: To evaluate hepatitis B and hepatitis C serology findings and to determine the current prevalence of those who had applied to the Turkish hospital in Mogadishu, Somalia.

Material and Method: The demographic findings and hepatitis test results (HBsAg, antiHBs antibody, and anti-HCV) of the patients were recorded retrospectively from their files.

Results: A total of 152,266 patients, 75,903 (49.8%) male and 76,363 (50.2%) female, with a mean age of 34 (31/61) years, were included in our study. 1,278 (1.9%) of 67,749 patients who were tested for anti-HCV were found to be positive. 27,208 patients (32.2%) were found to have developed natural or vaccine immunity for HBV. It was found that those with anti-HCV (+) were generally older than 55 years and that those with HBsAg (+) were generally younger than 55 years [OR: 6.02 (5.28-6.87): 95%, CI].

Conclusion: In our study, it can be said that HBsAg and anti-HCV seroprevalence (8.2% and 1.9%, respectively) in the Somalia population is still above desired levels. The fact that anti-Hbs antibody levels are at 32.2% underscores the importance of the development and popularization of vaccination programs.

Anahtar Kelimeler

• HBV
• HCV
• Seroprevalence
• Somali

Somali'de Bulunan “Mogadişu Türkiye Recep Tayyip Erdoğan Eğitim ve Araştırma Hastanesi” Kliniklerine Başvuran Hastalarda Hepatit B ve Hepatit C Virüs Enfeksiyonu Seroprevalansının Retrospektif Olarak Değerlendirilmesi

Öz

Amaç: Somali Mogadişu'daki Türk hastanesine başvuranların hepatit B ve hepatit C seroloji bulgularını değerlendirmeyi ve mevcut prevalansının belirlenmesi.

Gereç ve Yöntemler: Hastaların demografik bulguları ve hepatit test sonuçları (HBsAg, anti-HBs antikoru ve anti-HCV) dosyalarından geriye dönük olarak kaydedildi.

Bulgular: Çalışmamıza yaş ortalaması 34 (31/61) yıl olan 75.903 (%49,8) erkek ve 76.363 (%50,2) kadın olmak üzere toplam 152.266 hasta dahil edildi. Anti-HCV için test edilen 67.749 hastanın 1.278'i (%1,9) pozitif bulundu. 27.208 hastanın (%32,2) HBV için doğal veya aşı bağışıklığı geliştirdiği bulundu. Anti-HCV (+) olanların genel olarak 55 yaşından büyük, HBsAg (+) olanların ise genellikle 55 yaşından küçük olduğu [OR: 6,02 (5,28-6,87): %95, CI] bulundu.

Sonuç: Çalışmamızda Somali popülasyonunda HBsAg ve anti-HCV seroprevalansının (sırasıyla %8,2 ve %1,9) halen istenilen seviyelerin üzerinde olduğu söylenebilir. Anti-Hbs antikor düzeylerinin %32,2 düzeyinde olması, aşılama programlarının geliştirilmesinin ve yaygınlaştırılmasının önemini vurgulamaktadır.

Anahtar Kelimeler

• HBV
• HCV
• Seroprevalans
• Somali

Kaynakça

1. 1. Daw MA, Dau AA. Hepatitis C virus in Arab world: a state of concern. Scientific World Journal 2012; 719494.
2. 2. Hassan-Kadle MA. The Diagnostic Challenges, Possible Etiologies and Lack of Researches of Hepatocellular Carcinoma in Somalia. Open J Gastroenterol 2017;07:115-123.
3. 3. Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009;50:661-662.
4. 4. Rossi C, Shrier I, Marshall L et al. Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees: a systematic review and meta-analysis. PLoS One 2012;7:e44611.
5. 5. Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003;23:39-46.
6. 6. World Health Organization, Organization. WH. Prevention and control of viral hepatitis infection: framework for global action 2012 https://apps.who.int/iris/handle/10665/130012 (erişim tarihi: 5.06.2021)
7. 7. Ott JJ, Stevens GA, Groeger J, Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212-2219.
8. 8. Centers for Disease Control and Prevention (CDC). Adverse childhood experiences reported by adults --- five states, 2009. MMWR Morb Mortal Wkly Rep 2010;59:1609-1613.

9. 9. Museru O, Franco-Paredes C. Epidemiology and clinical outcomes of hepatitis B virus infection among refugees seen at a U.S. travel medicine clinic: 2005-2008. Travel Med Infect Dis 2009;7:171-174.
10. 10. Museru OI, Vargas M, Kinyua M. Hepatitis B virus infection among refugees resettled in the U.S.: high prevalence and challenges in access to health care. J Immigr Minor Heal 2010;12:823-827.
11. 11. Roberts H, Kruszon-Moran D, Ly KN et al. Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988-2012. Hepatology 2016; 63:388-397.
12. 12. Hassan-Kadle MA, Osman MS, Ogurtsov PP. Epidemiology of viral hepatitis in Somalia: Systematic review and metaanalysis study. World J Gastroenterol 2018;24:3927-3957.
13. 13. Lın X, Robinson N, Thursz M et al. Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: Review of disease progression. J Gastroenterol Hepatol 2005;20: 833- 843.
14. 14. Ladep NG. Problem of hepatocellular carcinoma in West Africa. World J Hepatol 2014;6:783.
15. 15. Yang JD, Mohamed EA, Aziz AOA et al. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol 2017;2:103-111.
16. 16. Lemoine M, Thursz MR. Battlefield against hepatitis B infection and HCC in Africa. J Hepatol 2017;66: 645-654.
17. 17. Kew MC. Epidemiology of hepatocellular carcinoma in subSaharan Africa. Ann Hepatol 2013;12:173-182.
18. 18. Crocker-Buque T, Pollock AM. Appraising the quality of subSaharan African cancer registration systems that contributed to GLOBOCAN 2008: a review of the literature and critical appraisal. J R Soc Med 2015; 26;108:57-67.
19. 19. Dalgard O, Mauss S. No strategy to meet the HCV epidemic. BMC Infect Dis 2014;14:S2.
20. 20. Demsiss W, Seid A, Fiseha T. Hepatitis B and C: Seroprevalence, knowledge, practice and associated factors among medicine and health science students in Northeast Ethiopia. PLoS One 2018;13:e0196539.
21. 21. Pérez-Romero M, Sánchez-Quijano A, Lissen E. Transmission of Hepatitis C Virus. Ann Intern Med 1990;113:411-412.
22. 22. Belyhun Y, Maier M, Mulu A. Hepatitis viruses in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis 2016;16:761.
23. 23. Averhoff FM, Glass N, Holtzman D. Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States. Clin Infect Dis 2012;55:10-15.
24. 24. Bile K, Mohamud O, Aden C et al. The risk for hepatitis A, B, and C at two institutions for children in Somalia with different socioeconomic conditions. Am J Trop Med Hyg 1992;47: 357- 364.
25. 25. Daw MA, Dau AA, Agnan MM. Influence of healthcare-associated factors on the efficacy of hepatitis C therapy. Scientific World Journal 2012;2012:580216.